UPDATE 1-Baxter to start production in Germany of BioNTech/Pfizer vaccine by early March
Wednesday, 13 January 2021, 13:21:05
Baxter International aims to start making the COVID-19 vaccine from BioNTech and Pfizer in Germany within weeks, it said on Wednesday, joining efforts to ramp up output of the first such vaccine to win widespread approval from regulators.
Wednesday, 13 January 2021, 00:37:21
A Chicago federal judge dismissed a proposed class action against Baxter International Inc on Tuesday, writing that shareholders failed to claim the medical equipment company and its top executives knew the company was not accurately recording foreign transactions.
Baxter Biopharma Solutions: Sterile Mfg. – Novavax COVID-19 Vaccine
Monday, 11 January 2021, 14:43:37
Agreement will help increase commercial production and promote access in United Kingdom and European markets Manufacturing to take place at Baxter’s state-of-the-art Halle/Westfalen, Germany facility DEERFIELD, IL (STL.News) Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, today announced that Baxter BioPharma Solutions has entered into an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M™ adjuvant. Baxter BioPharma Solutions is a premier contract manufacturing organization that specializes in parenteral (injectable) pharmaceuticals, including vaccines. The agreement is expected to advance commercial-scale manufacturing essential for the vaccine’s production and distribution in the United Kingdom and European markets. Novavax’ COVID-19 vaccine candidate is currently in phase 3 trials and has not yet been authorized or approved for use. “The quest to develop vaccines for COVID-19 has reinforced the opportunity for industry partners to work together and contribute their unique capabilities and expertise for the benefit of all,” said Marie Keeley, vice president, Baxter BioPharma Solutions. “We welcome the opportunity to work with an innovative company like Novavax and look forward to helping bring their vaccine candidate to the market.” According to Novavax, NVX-CoV2373 contains a full-length, prefusion spike protein made using Novavax’ recombinant nanoparticle technology and the company’s proprietary saponin-based Matrix-M™ adjuvant.
Hall of Fame CIO Paul Martin Joins Ping Identity’s Board of Directors
Thursday, 7 January 2021, 15:00:00
DENVER–(BUSINESS WIRE)–Ping Identity (NYSE: PING), the Intelligent Identity solution for the enterprise, announced that Paul E. Martin has joined the company’s board of directors. Martin is an acclaimed IT visionary with international experience, boardroom acumen, and award-winning IT innovation accolades. Martin most recently served as CIO and senior vice president for Baxter International Inc., where he led the company’s global IT strategy, operations, security and processes. Previous exper
— Business Wire
Global Soft Tissue Repair Market- Featuring 3M Co., Arthrex Inc., and Baxter International Inc. Among Others
Wednesday, 6 January 2021, 20:18:00
LONDON–(BUSINESS WIRE)– #GlobalSoftTissueRepairMarket–The Soft Tissue Repair Market will grow by USD 10.44 bn during 2020-2024
— Business Wire
We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.